The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The tumoral molecular landscape of long-term survivors with isocitrate dehydrogenase wildtype glioblastoma: Lessons from ETERNITY (EORTC 1419).
 
Michael Weller
Honoraria - Bayer; Novocure
Consulting or Advisory Role - AstraZeneca (I); Bayer (I); Biodexa (I); Curevac; Janssen (I); LEO Pharma (I); Medac; Medac (I); Novartis; Novartis; Novartis (I); Orbus Therapeutics; Pfizer (I); Philogen; Roche (I); Sandoz; Seagen (I); Seagen (I); Servier; Servier (I)
Research Funding - BMS (Inst); Novartis (Inst); Quercegen Pharmaceuticals (Inst); Versameb (Inst)
 
Dennis Friedel
No Relationships to Disclose
 
Joerg Felsberg
No Relationships to Disclose
 
Dorothee Gramatzki
No Relationships to Disclose
 
Abigail Suwala
No Relationships to Disclose
 
Jennifer Clarke
Consulting or Advisory Role - Agios (Inst); SERVIER (Inst)
Research Funding - Agios (Inst); Merck (Inst); SERVIER (Inst)
 
Oliver Schnell
No Relationships to Disclose
 
Giuseppe Lombardi
Consulting or Advisory Role - Bayer; Brain Health Solutions; Braun Travacare; CarThera; Cecava; Genenta Science; GlaxoSmithKline; health4u; Janssen Oncology; Novartis; Novocure; SERVIER; TME Pharma
Speakers' Bureau - Bayer; Novocure; SERVIER
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; SERVIER
 
Wolfgang Wick
Consulting or Advisory Role - GlaxoSmithKline; Roche/Genentech (Inst); SERVIER
Research Funding - Apogenix (Inst); Pfizer (Inst); Roche (Inst)
 
Dietmar Krex
No Relationships to Disclose
 
Martin Sill
Employment - Heidelberg Epignostix
 
Thierry Gorlia
No Relationships to Disclose
 
Matthias Preusser
Honoraria - Abbvie; Adastra Pharmaceuticals; AstraZeneca; Bayer; BMJ Journals; Bristol-Myers Squibb; CMC Contrast; Daiichi Sankyo; Gan & Lee; Gerson Lehrman Group; GlaxoSmithKline; Lilly; Medahead; MedMedia; Merck Sharp & Dome; Mundipharma; Novartis; Roche; Sanofi; SERVIER; Telix Pharmaceuticals; Tocagen
Consulting or Advisory Role - AbbVie; Adastra Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; CMC Contrast; Daiichi Sankyo/Astra Zeneca; Gan & Lee; Gerson Lehrman Group; GlaxoSmithKline; Lilly; Merck Sharp & Dome; Mundipharma; Novartis; Roche; Sanofi; SERVIER; Tocagen
Research Funding - AbbVie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme; Novartis (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Mundipharma; Roche; SERVIER
 
Patrick Wen
Consulting or Advisory Role - Alexion Pharmaceuticals; Anheart Therapeutics; AstraZeneca; Bayer; Black Diamond Therapeutics; Bristol Myers Squibb Foundation; Celularity; Chimerix; Day One Biopharmaceuticals; Fore Biotherapeutics; Genenta Science; GlaxoSmithKline; Kintara Therapeutics; Merck; Mundipharma; Mundipharma; Novocure; Novocure; Nuvation Bio; Sapience Therapeutics; Servier; Servier; SymBio Pharmaceuticals; Tango Therapeutics; Telix Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bayer (Inst); Black Damond (Inst); Bristol-Myers Squibb/Medarex (Inst); Chimerix (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Global Coalition for Adaptive Research (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Philogen (Inst); Quadriga Biosciences (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Emilie Le Rhun
Honoraria - Bayer (I); Novocure (I); Pierre Fabre
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Biodexa Pharmaceuticals; CureVac (I); Janssen; Leo Pharma; Medac; Medac (I); Novartis; Novartis (I); Orbus Therapeutics (I); Pfizer; Philogen (I); Roche; Roche (I); Sandoz (I); Seagen; SERVIER; SERVIER (I)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Quercegen Pharmaceuticals (Inst); Versameb (Inst)
 
Andreas von Deimling
Stock and Other Ownership Interests - Heidelberg Epignostix
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bayer
Patents, Royalties, Other Intellectual Property - DNA-methylation based method for classifying tumor species EP16710700; Patent for BRAFV600E antibody VE1 administered by the German Cancer Center (DKFZ); Patent for IDH1R132H antibody H09 administered by the German Cancer Center (DKFZ)
Travel, Accommodations, Expenses - Roche
 
Guido Reifenberger
No Relationships to Disclose
 
David Reuss
Patents, Royalties, Other Intellectual Property - Cell Marque CorporaYon
(OPTIONAL) Uncompensated Relationships - Bruker Daltonics
 
Roberta Rudà
Honoraria - CureVac; Genenta Science; Novocure; SERVIER
Research Funding - Bayer (Inst)
 
Caroline Hertler
Research Funding - Swiss Cancer League; Swiss National Fond
 
for the EORTC 1419 ETERNITY Study Group
No Relationships to Disclose